EICHOR
● Active Not Recruiting
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
Condition: Focal Onset Seizure · Sponsor: SK Life Science, Inc.
About this study
Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (19)
| Arizona Neuroscience Research | Phoenix, Arizona, United States | — |
| Center For Neurosciences | Tucson, Arizona, United States | — |
| Clinical Trials Inc | Little Rock, Arkansas, United States | — |
| Neuro Pain Medical Center | Fresno, California, United States | — |
| Hoag Physician Partners | Newport Beach, California, United States | — |
| Hartford Hospital | Hartford, Connecticut, United States | — |
| Yale School of Medicine - Yale-New Haven Hospital | New Haven, Connecticut, United States | — |
| Elite Clinical Research | Miami, Florida, United States | — |
| Knight Neurology | Rockledge, Florida, United States | — |
| Consultants In Epilepsy and Neurology | Boise, Idaho, United States | — |
| Bluegrass Epilepsy Research LLC | Lexington, Kentucky, United States | — |
| Louisiana State University Health Sciences | Shreveport, Louisiana, United States | — |
+ 7 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06453213